These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28810186)

  • 21. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
    Lin NU; Borges V; Anders C; Murthy RK; Paplomata E; Hamilton E; Hurvitz S; Loi S; Okines A; Abramson V; Bedard PL; Oliveira M; Mueller V; Zelnak A; DiGiovanna MP; Bachelot T; Chien AJ; O'Regan R; Wardley A; Conlin A; Cameron D; Carey L; Curigliano G; Gelmon K; Loibl S; Mayor J; McGoldrick S; An X; Winer EP
    J Clin Oncol; 2020 Aug; 38(23):2610-2619. PubMed ID: 32468955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.
    Kroep JR; Linn SC; Boven E; Bloemendal HJ; Baas J; Mandjes IA; van den Bosch J; Smit WM; de Graaf H; Schröder CP; Vermeulen GJ; Hop WC; Nortier JW
    Neth J Med; 2010 Sep; 68(9):371-6. PubMed ID: 20876920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
    Lin NU; Diéras V; Paul D; Lossignol D; Christodoulou C; Stemmler HJ; Roché H; Liu MC; Greil R; Ciruelos E; Loibl S; Gori S; Wardley A; Yardley D; Brufsky A; Blum JL; Rubin SD; Dharan B; Steplewski K; Zembryki D; Oliva C; Roychowdhury D; Paoletti P; Winer EP
    Clin Cancer Res; 2009 Feb; 15(4):1452-9. PubMed ID: 19228746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.
    de Azambuja E; Zardavas D; Lemort M; Rossari J; Moulin C; Buttice A; D'Hondt V; Lebrun F; Lalami Y; Cardoso F; Sotiriou C; Gil T; Devriendt D; Paesmans M; Piccart-Gebhart M; Awada A
    Ann Oncol; 2013 Dec; 24(12):2985-9. PubMed ID: 24013582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
    Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H
    J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
    Lin NU; Carey LA; Liu MC; Younger J; Come SE; Ewend M; Harris GJ; Bullitt E; Van den Abbeele AD; Henson JW; Li X; Gelman R; Burstein HJ; Kasparian E; Kirsch DG; Crawford A; Hochberg F; Winer EP
    J Clin Oncol; 2008 Apr; 26(12):1993-9. PubMed ID: 18421051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
    Chiba A; Shimizu S; Yoshida A; Inaba M; Matsuura H; Ino H; Suganuma N; Inari H; Yamanaka T; Kuroda K; Mukaibashi T; Matsuo A; Kojima I
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1675-9. PubMed ID: 23152018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
    Romero Carreño E; Marcos Rodríguez JA; Santana Martínez S; de la Cruz Merino L
    Farm Hosp; 2016 Mar; 40(2):134-6. PubMed ID: 26980172
    [No Abstract]   [Full Text] [Related]  

  • 29. A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
    Takano T; Tsurutani J; Takahashi M; Yamanaka T; Sakai K; Ito Y; Fukuoka J; Kimura H; Kawabata H; Tamura K; Matsumoto K; Aogi K; Sato K; Nishio K; Nakagawa K; Saeki T
    Breast; 2018 Aug; 40():67-75. PubMed ID: 29698927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
    Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
    Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases.
    Wang C; Xiang J; Zhang Q; Li J; Liu Y; Liu J
    Drug Des Devel Ther; 2024; 18():909-917. PubMed ID: 38545432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
    Riemsma R; Forbes CA; Amonkar MM; Lykopoulos K; Diaz JR; Kleijnen J; Rea DW
    Curr Med Res Opin; 2012 Aug; 28(8):1263-79. PubMed ID: 22738819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Over 17-month complete clinical brain response with a well-tolerated lapatinib plus capecitabine combination in a very young patient afflicted by HER2-positive metastatic breast cancer.
    Sini V; Menghi A; Cursano MC; Mandolini PL; Lanza R
    Tumori; 2013; 99(6):273e-7e. PubMed ID: 24503802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.
    Musolino A; Naldi N; Dieci MV; Zanoni D; Rimanti A; Boggiani D; Sgargi P; Generali DG; Piacentini F; Ambroggi M; Cagossi K; Gianni L; Sarti S; Bisagni G; Ardizzoni A; Conte PF; Guarneri V
    Pharmacogenomics J; 2016 Oct; 16(5):472-7. PubMed ID: 27378608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
    Glück S; Castrellon A
    Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
    Pircher M; Mlineritsch B; Fridrik MA; Dittrich C; Lang A; Petru E; Weltermann A; Thaler J; Hufnagl C; Gampenrieder SP; Rinnerthaler G; Ressler S; Ulmer H; Greil R
    Anticancer Res; 2015 Jan; 35(1):517-21. PubMed ID: 25550597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
    Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
    Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.